Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.77 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579418 | 0.95 | CYP4A11 (0.79) | CYP4A11CYP4F2KMT2AALDH1A1GAA | |
| SCHEMBL15586041 | 0.93 | CYP4A11 (0.75) | CYP4A11CYP4F2KMT2AALDH1A1GAA | |
| SCHEMBL11493064 | 0.89 | CYP4A11 (0.75) | CYP4A11CYP4F2KMT2AALDH1A1GAA | |
| SCHEMBL9332759 | 0.87 | CYP4A11 (1.00) | CYP4A11CYP4F2KMT2AALDH1A1GAA | |
| SCHEMBL23521630 | 0.86 | ALDH1A1 (0.66) | CYP4A11CYP4F2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL4578656 | 0.86 | CYP4F2 (0.66) | CYP4A11CYP4F2KMT2AALDH1A1GAA | |
| SCHEMBL15581416 | 0.86 | CYP4A11 (0.66) | CYP4A11CYP4F2KMT2AALDH1A1GAA | |
| SCHEMBL15581442 | 0.86 | CYP4A11 (0.66) | CYP4A11CYP4F2KMT2AALDH1A1GAA | |
| SCHEMBL15522740 | 0.86 | CYP4F2 (0.66) | CYP4A11CYP4F2ALDH1A1GAAGFER | |
| SCHEMBL9673644 | 0.84 | CYP4A11 (0.63) | CYP4A11CYP4F2CA2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979675-B | Small molecular sulfur-containing heterocyclic compound | 维眸生物科技（上海）有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-111217834-B | Nitroxide derivatives of ROCK kinase inhibitors | 维眸生物科技（上海）有限公司 | 2021-10-26 | — | — | CN | disclosed |
| CN-112979675-A | Small-molecule sulfur-containing heterocyclic compound | 维眸生物科技（上海）有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021115495-A1 | SMALL-MOLECULE SULFUR-CONTAINING HETEROCYCLIC COMPOUND | 维眸生物科技（上海）有限公司 | 2021-06-17 | — | — | WO | disclosed |
| CN-111217834-A | Nitroxide derivatives of ROCK kinase inhibitors | 维眸生物科技（上海）有限公司 | 2020-06-02 | — | — | CN | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| WO-2014041424-A1 | HISTONE DEACETYLASE INHIBITORS FOR ENHANCING ACTIVITY OF ANTIFUNGAL AGENTS | METHYLGENE INC. (CA) | 2014-03-20 | — | — | WO | disclosed |
| WO-2007008037-A1 | NOVEL CHROMEN-2-ONE BASED HYDROXAMIC ACID DERIVATIVES HAVING ANTI-INFLAMMATORY ACTIVITY, THE PREPARATION THEREOF AND A COMPOSITION CONTAINING THE SAME FOR TREATING INFLAMMATORY DISEASE | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2007-01-18 | — | — | WO | disclosed |
| US-6632921-B1 | Administering as topical fungicide against Candida | G. D SEARLE & CO | 2003-10-14 | — | — | US | disclosed |
| EP-0882029-B1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1173415-A1 | DIPHENYLUREA DERIVATIVES | AstraZeneca AB (SE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064866-A1 | DIPHENYLUREA DERIVATIVES | ASTRAZENECA AB (SE) | 2000-11-02 | — | — | WO | disclosed |
| US-6090836-A | DIETETICS; ADJUSTMENT OF TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| US-5942600-A | COMPOUNDS WITH SELECTIVE CONTROL OF FUNGAL ORGANISM CANDIDA ALBICANS FOR TREATMENT IN HUMANS, FOR EXAMPLE THOSE WITH WEAKENED IMMUNE SYSTEMS DUE TO AIDS; SPECIES-SPECIFIC CONTROL | G. D. SEARLE & CO. (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0882029-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | HDAC1, HDAC5, HDAC7 | CYP4A11 840/4885CYP4F2 2410/4885KMT2A 54/4885 |
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | CYP4A11 310/4885CYP4F2 1652/4885KMT2A 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.